In the past week, AUTL stock has gone down by -1.72%, with a monthly gain of 2.23% and a quarterly plunge of -49.34%. The volatility ratio for the week is 5.54%, and the volatility levels for the last 30 days are 6.91% for Autolus Therapeutics plc ADR The simple moving average for the last 20 days is -1.86% for AUTL’s stock, with a simple moving average of -38.83% for the last 200 days.
Is It Worth Investing in Autolus Therapeutics plc ADR (NASDAQ: AUTL) Right Now?
The 36-month beta value for AUTL is at 2.01. Analysts have varying views on the stock, with 8 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AUTL is 236.67M, and currently, shorts hold a 3.65% of that float. The average trading volume for AUTL on January 24, 2025 was 1.87M shares.
AUTL) stock’s latest price update
The stock of Autolus Therapeutics plc ADR (NASDAQ: AUTL) has increased by 6.02 when compared to last closing price of 2.16.Despite this, the company has seen a loss of -1.72% in its stock price over the last five trading days. globenewswire.com reported 2025-01-17 that LONDON, Jan. 17, 2025 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces an oral presentation and three poster presentations accepted to the 2025 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, being held from February 12-15, 2025, in Hawai’i Convention Center, Honolulu, HI. “Building on our data presented at ASH in December, we come to Tandem with an updated health economic cost model directly comparing the cost of adverse events of AUCATZYL® versus other CAR-T cell therapies, which demonstrates that the shorter duration and lower incidence of CRS and ICANS contributes to a reduction in healthcare costs,” said Dr. Christian Itin, Chief Executive Officer of Autolus.
Analysts’ Opinion of AUTL
Many brokerage firms have already submitted their reports for AUTL stocks, with Goldman repeating the rating for AUTL by listing it as a “Buy.” The predicted price for AUTL in the upcoming period, according to Goldman is $7.60 based on the research report published on November 18, 2024 of the previous year 2024.
Redburn Atlantic, on the other hand, stated in their research note that they expect to see AUTL reach a price target of $13. The rating they have provided for AUTL stocks is “Buy” according to the report published on November 15th, 2024.
Deutsche Bank gave a rating of “Buy” to AUTL, setting the target price at $10 in the report published on November 09th of the previous year.
AUTL Trading at -15.16% from the 50-Day Moving Average
After a stumble in the market that brought AUTL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -68.93% of loss for the given period.
Volatility was left at 6.91%, however, over the last 30 days, the volatility rate increased by 5.54%. Over the last 50 days, in opposition, the stock is trading -43.32% lower at present.
During the last 5 trading sessions, AUTL fell by -1.72%, which changed the moving average for the period of 200-days by -59.11% in comparison to the 20-day moving average, which settled at $2.33. In addition, Autolus Therapeutics plc ADR saw -2.55% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AUTL starting from Martin Pule, who proposed sale 698,741 shares at the price of $4.23 back on Sep 16 ’24. After this action, Martin Pule now owns shares of Autolus Therapeutics plc ADR, valued at $2,955,674 using the latest closing price.
Stock Fundamentals for AUTL
Current profitability levels for the company are sitting at:
- -17.4 for the present operating margin
- 0.52 for the gross margin
The net margin for Autolus Therapeutics plc ADR stands at -22.77. The total capital return value is set at -0.27. Equity return is now at value -82.20, with -43.81 for asset returns.
Based on Autolus Therapeutics plc ADR (AUTL), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at -3.7. The debt to equity ratio resting at 0.11. The interest coverage ratio of the stock is -2.94.
Currently, EBITDA for the company is -156.77 million with net debt to EBITDA at 3.36. When we switch over and look at the enterprise to sales, we see a ratio of 0.39. The receivables turnover for the company is 11.95for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.64.
Conclusion
In conclusion, Autolus Therapeutics plc ADR (AUTL) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
